Skip to content

Asarina Pharma AB (publ) Interim Report, Q1 2019 released

(Stockholm May 20, 2019) Asarina Pharma CEO Peter Nordkild: “We have made a strong start to 2019. This Quarter we have strengthened our team and capabilities, yet still maintained strict financial management – leading to a solid cash position at the end of the First Quarter.”

Financial Highlights

The company maintained a strict management of its costs. The total cash position at the end of the Quarter was SEK 128.9 million.

The Quarter in Brief

PMDD: Our Phase IIb study in our lead indication, Premenstrual Dysphoric Disorder (PMDD) made good progress, with a drop-out rate of less than 15% compared to more than 30% average in other late stage clinical PMDD studies. We expect topline results in early 2020.

MENSTRUAL MIGRAINE: Our Phase IIa proof-of-concept study in Menstrual Migraine (MM) is on schedule to start enrolment of patients in July. A CTA has been submitted in Sweden and CTAs will be submitted in Denmark and Finland shortly.

AUTOINJECTORS: We are focusing on identifying the best possible autoinjector to administer Sepranolone in future studies and expect to select the final autoinjector for Phase III studies and commercialization in June.

TOURETTE SYNDROME: We published exciting data on Tourette syndrome in March. The data indicate that Sepranolone reduces tics in an animal model of Tourette syndrome on a par with Haldol, the current first-line treatment, without inducing any motor side effects.

For further information see the attached, plus please visit